Alkyl-Lysophospholipids

Chemical structure of edelfosine, an alkyl-lysophospholipid being studied for its potential use as a pharmaceutical drug

Alky-lysophospholipids (ALPs) are synthetic analogs of lysophosphatidylcholines (LPCs), also called lysolecithins. They are synthesized by replacing the acyl-group within the LPC with an alkyl group.^[1] In contrast to LPCs, ALPs are metabolically very stable.^[1]^[2]

ALPs are being studied for their potential antineoplastic (anti-cancer)^[1] and immune-modulating effects.^[2] Their anti-tumor effects are due to modulation of intracellular signalling pathways, inducing apoptosis.^[3] It is highly selective, sparing healthy cells.^[2] Several examples including edelfosine, miltefosine, and perifosine are under development as drugs against cancer and other diseases.

References

↑ ^1.0 ^1.1 ^1.2 Munder, PG; Modolell M; Adreesen R; Weltzien HU; Westphal O (1979). "Lysophosphatidylcholine (Lysolecithin) and its Synthetic Analogues. Immunemodulating and Other Biologic Effects". Springer Seminars in Immunopathology 203 (2): 187–203. doi:10.1007/BF01891668.
↑ ^2.0 ^2.1 ^2.2 Houlihan, W; Lohmeyer M; Workman P; Cheon SH (1995). "Phospholipid antitumor agents". Medicinal Research Reviews 15 (3): 157–223. doi:10.1002/med.2610150302. PMID 7658750.
↑ van Blitterswijk, W; Verheij M (2008). "Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects". Current Pharmaceutical Design 14 (21): 2061–74. doi:10.2174/138161208785294636. PMID 18691116.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Alkyl-lysophospholipids. Read more

[Munder-1979-1] 1.0 ^1.1 ^1.2 Munder, PG; Modolell M; Adreesen R; Weltzien HU; Westphal O (1979). "Lysophosphatidylcholine (Lysolecithin) and its Synthetic Analogues. Immunemodulating and Other Biologic Effects". Springer Seminars in Immunopathology 203 (2): 187–203. doi:10.1007/BF01891668.

[Houlihan-1995-2] 2.0 ^2.1 ^2.2 Houlihan, W; Lohmeyer M; Workman P; Cheon SH (1995). "Phospholipid antitumor agents". Medicinal Research Reviews 15 (3): 157–223. doi:10.1002/med.2610150302. PMID 7658750.

[van-Blitterswijk-2008-3] van Blitterswijk, W; Verheij M (2008). "Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects". Current Pharmaceutical Design 14 (21): 2061–74. doi:10.2174/138161208785294636. PMID 18691116.

[1]

[2]

[3]